u/emeka_chowdhury

Disagree with reading anything into that. One value, one morning, and you changed two other things in the same window.

Push back: PCOS as a diagnosis and insulin resistance as a finding are not interchangeable, and the thread is using them as one.

potency testing on the finished preparation is the thing to ask for

503A is patient-specific, 503B is outsourcing facility, they are not the same thing

the related substances line is where the story is

Disagree that a lower number is automatically worse. A conservative claim that survives testing is worth more than an optimistic one that does not.

That is the catalogue certificate rather than the batch-specific one. Same layout, completely different status.

Have you asked a pharmacist about the absorption question specifically?

Disagree — a 503B being registered does not make its preparations equivalent to an approved product.

Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.

UV at 214nm sees the peptide bond and picks up almost everything; at 280nm you are looking at aromatics only. Which wavelength the number came from is part of the number.

I would not read a rounded figure as evasive. Plenty of documents round to one decimal as house style.

UV at 214nm sees the peptide bond and picks up almost everything; at 280nm you are looking at aromatics only. Which wavelength the number came from is part of the number.

the trend line matters more than any single value

This. Albumin binding and modification are why the half-life is what it is, and it is a design decision rather than an accident.

same lab, same conditions, or you are comparing noise

gastric emptying slows, it does not stop

formulary_fighter is right that mechanism gives direction and not magnitude. Worth pinning.

Did you ask for the batch-specific document, or is this the catalogue one?

fasting state and time of day change more than people expect

Agreed — and standardising the draw conditions is the cheapest improvement available.

What did the repeat show?

tolerance to the gastric effect develops, appetite effect largely persists

the ranking formula is published, go and read it

nobody here is paid, including the moderators

a 503B has to register and report, so there is a paper trail to ask for

Same lab as the previous draw?

Disagree that a lower number is automatically worse. A conservative claim that survives testing is worth more than an optimistic one that does not.

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

assay method matters, especially between different labs

LC-MS gives you identity; UV purity gives you a relative quantity. A document with the first and not the second, or the reverse, is answering half the question.

What concentration is on the label, and does it match what you were expecting?

nausea profile in the combination trials is the thing to read carefully

HPLC-UV and LC-MS answer different questions

Push back: a value just outside a reference interval is a common finding in healthy people. It is a reason to repeat.

area% is not mass%, and the difference is the whole game

tolerance to the gastric effect develops, appetite effect largely persists

ask whether the lab changed its assay between your two draws

Is water content on the document? It changes your concentration arithmetic.

UV at 214nm sees the peptide bond and picks up almost everything; at 280nm you are looking at aromatics only. Which wavelength the number came from is part of the number.

draw at the same point in the week if you want comparability

Agreed — and standardising the draw conditions is the cheapest improvement available.

Asked a pharmacist about the absorption question rather than the internet. Ten minutes, clear answer, done.

Same view — ApoB if you add one thing. It answers a question the standard panel only gestures at.